Zanubrutinib for the treatment of Waldenström Macroglobulinemia
- 1 December 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Hematology
- Vol. 13 (12), 1303-1310
- https://doi.org/10.1080/17474086.2020.1851184
Abstract
Introduction: Waldenström Macroglobulinaemia (WM) is a heterogeneous, incurable condition which often relapses after chemoimmunotherapy. Novel therapies such as Bruton tyrosine-kinase (BTK) inhibitors have shown to be efficacious in treating WM but with an established, significant toxicity profile seen in the first-generation inhibitor Ibrutinib. Zanubrutinib is a selective, potent BTK inhibitor with the potential to reduce toxicity and improve efficacy. Areas covered: This review examines the activity of Zanubrutinib in treating treatment-naïve and relapsed refractory WM and it’s toxicity profile when compared to Ibrutinib. Outcomes from the AU003 and ASPEN studies will be examined in detail including a particular focus on MYD88WT and CXCR4WHIM disease. Strengths and weaknesses of this treatment approach will be highlighted and future directions for research will be identified. Expert opinion: Zanubrutinib induces deeper responses and have greater activity in MYD88WT and CXCR4WHIM WM. Zanubrutinib also has a favorable toxicity profile when compared to Ibrutinib. This may potentially translate to lower discontinuation rates, improved quality of life and ultimately longer progression-free survival in patients with WM.Keywords
This publication has 49 references indexed in Scilit:
- Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)Blood, 2013
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaBlood, 2013
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaThe New England Journal of Medicine, 2013
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenström Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic LymphomaJournal of Clinical Oncology, 2013
- Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2011
- Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström MacroglobulinemiaJournal of Clinical Oncology, 2010
- Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180Journal of Clinical Oncology, 2009
- Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and CyclophosphamideJournal of Clinical Oncology, 2007
- Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248Clinical Cancer Research, 2007